^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    LRP1B mutation + TMB-H

    i
    Other names: Low density lipoprotein-related protein 1B, LRPDIT, LRP1B, LDL receptor related protein 1B, Low-density lipoprotein receptor-related protein 1B, LRP-1B, TMB | Tumor Mutational Burden
    Entrez ID:
    53353
    Related biomarkers:
    Expression
    Mutation
    CNA
    Others
    9ms
    An Investigation of the Immune Microenvironment and Genome during Lung Adenocarcinoma Development. (PubMed, J Cancer)
    Mutations in EGFR and LRP1B could potentially establish an immune niche that fosters tumor growth. PAMs in LUAD may accelerate disease progression by promoting T cell differentiation into an exhausted state.
    Journal • Tumor mutational burden • PD(L)-1 Biomarker • IO biomarker
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • CD8 (cluster of differentiation 8) • LRP1B (LDL Receptor Related Protein 1B) • CD4 (CD4 Molecule) • CD68 (CD68 Molecule)
    |
    PD-L1 expression • EGFR mutation • TMB-H • LRP1B mutation • LRP1B mutation + TMB-H • EGFR mutation + LRP1B mutation
    over2years
    LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma. (PubMed, Medicine (Baltimore))
    Collectively, our results revealed that LRP1B mutation was related to high TMB value and poor prognosis in LIHC, indicating that LRP1B mutation is probably helpful for the selection of immunotherapy and prognosis prediction in LIHC.
    Journal • Tumor Mutational Burden • BRCA Biomarker • IO biomarker
    |
    TMB (Tumor Mutational Burden) • BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • LRP1B (LDL Receptor Related Protein 1B)
    |
    BRCA1 mutation • TMB-H • LRP1B mutation • LRP1B mutation + TMB-H
    over3years
    [VIRTUAL] Association of TP53 and LRP1B co-mutation status with response to immunotherapy in lung squamous cell carcinoma (AACR 2021)
    TP53mut and LRP1Bmut, which accounted for a high proportion of LUSC, was associated with high TMB. And TP53wild and LRP1Bwild has better anti-PD-L1 outcome in LUSC. This might be related with a stronger activated dendritic cell and activated CD8 T cell infiltration despite lower TMB.
    Tumor Mutational Burden • PD(L)-1 Biomarker • IO biomarker
    |
    TP53 (Tumor protein P53) • TMB (Tumor Mutational Burden) • CDKN2A (Cyclin Dependent Kinase Inhibitor 2A) • CD8 (cluster of differentiation 8) • KMT2D (Lysine Methyltransferase 2D) • LRP1B (LDL Receptor Related Protein 1B) • FAT1 (FAT atypical cadherin 1) • MLL2 (Myeloid/lymphoid or mixed-lineage leukemia 2)
    |
    PD-L1 expression • TP53 mutation • TMB-H • KMT2D mutation • LRP1B mutation • LRP1B mutation + TMB-H